Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
Abstract Background Despite advancements in targeted therapy and immunotherapy, cutaneous melanoma continues to have a high mortality rate and poor prognosis, with therapies having limited efficacy in advanced melanoma. Therefore, it is crucial to develop novel therapeutics with proven clinical pote...
Saved in:
| Main Authors: | Dokyeong Kim, Junseong Park, Yoon-Seob Kim, Okcho Na, Minyoung Park, Songzi Zhang, Sumin Cho, Yeun-Jun Chung |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03675-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stabilization of GTSE1 by cyclin D1–CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis
by: Nelson García-Vázquez, et al.
Published: (2025-04-01) -
Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01) -
Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
by: Jonatan Kaszubski, et al.
Published: (2024-11-01) -
Hyperactivation of p53 contributes to mitotic catastrophe in podocytes through regulation of the Wee1/CDK1/cyclin B1 axis
by: Jie Feng, et al.
Published: (2024-12-01) -
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)